Cantor Fitzgerald Issues Positive Outlook for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a note issued to investors on Friday, May 2nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings of $3.61 per share for the year, up from their previous estimate of $3.53. Cantor Fitzgerald has a "Overweight" rating and a $90.00 price target on the stock. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million for the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%.

A number of other research firms have also weighed in on BMRN. Wedbush reaffirmed an "outperform" rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. StockNews.com raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Oppenheimer raised shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price on the stock in a report on Monday, February 24th. Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research note on Thursday, February 20th. Finally, Piper Sandler boosted their price target on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a research note on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $93.45.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock traded down $0.20 during mid-day trading on Monday, hitting $59.62. The stock had a trading volume of 188,760 shares, compared to its average volume of 1,859,145. BioMarin Pharmaceutical has a one year low of $52.93 and a one year high of $94.85. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $11.43 billion, a P/E ratio of 27.10, a P/E/G ratio of 0.61 and a beta of 0.27. The firm's 50 day moving average is $65.06 and its 200 day moving average is $65.50.

Insider Activity at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,295 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total transaction of $92,618.40. Following the completion of the sale, the chief accounting officer now directly owns 16,955 shares in the company, valued at $1,212,621.60. This represents a 7.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders have sold a total of 2,912 shares of company stock valued at $202,244 over the last ninety days. 0.85% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of large investors have recently added to or reduced their stakes in BMRN. Farther Finance Advisors LLC boosted its stake in BioMarin Pharmaceutical by 95.9% in the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 211 shares in the last quarter. LRI Investments LLC boosted its position in shares of BioMarin Pharmaceutical by 856.9% in the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 437 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in BioMarin Pharmaceutical by 71.2% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company's stock worth $37,000 after buying an additional 218 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $36,000. Finally, CIBC Private Wealth Group LLC raised its stake in BioMarin Pharmaceutical by 64.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock valued at $41,000 after buying an additional 233 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.